Coldstream Capital Management Inc. Purchases 627 Shares of West Pharmaceutical Services, Inc. (NYSE:WST)

Coldstream Capital Management Inc. raised its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 41.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 2,141 shares of the medical instruments supplier’s stock after buying an additional 627 shares during the period. Coldstream Capital Management Inc.’s holdings in West Pharmaceutical Services were worth $754,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Planned Solutions Inc. bought a new position in West Pharmaceutical Services in the 4th quarter valued at $39,000. Addison Advisors LLC boosted its position in West Pharmaceutical Services by 37.9% in the 3rd quarter. Addison Advisors LLC now owns 142 shares of the medical instruments supplier’s stock valued at $53,000 after buying an additional 39 shares during the last quarter. Livforsakringsbolaget Skandia Omsesidigt boosted its position in West Pharmaceutical Services by 90.0% in the 4th quarter. Livforsakringsbolaget Skandia Omsesidigt now owns 190 shares of the medical instruments supplier’s stock valued at $67,000 after buying an additional 90 shares during the last quarter. Lindbrook Capital LLC boosted its position in West Pharmaceutical Services by 46.0% in the 4th quarter. Lindbrook Capital LLC now owns 235 shares of the medical instruments supplier’s stock valued at $83,000 after buying an additional 74 shares during the last quarter. Finally, Tompkins Financial Corp bought a new position in West Pharmaceutical Services in the 4th quarter valued at $89,000. 93.90% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

WST has been the topic of a number of analyst reports. KeyCorp increased their price target on West Pharmaceutical Services from $440.00 to $470.00 and gave the company an “overweight” rating in a research note on Tuesday, February 13th. Jefferies Financial Group raised West Pharmaceutical Services from a “hold” rating to a “buy” rating and increased their price target for the company from $323.00 to $536.00 in a research note on Wednesday, February 7th. StockNews.com downgraded West Pharmaceutical Services from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Finally, UBS Group cut their price target on West Pharmaceutical Services from $400.00 to $375.00 and set a “neutral” rating on the stock in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $435.20.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $334.29 on Thursday. The company has a market capitalization of $24.35 billion, a PE ratio of 44.10, a PEG ratio of 5.95 and a beta of 1.05. West Pharmaceutical Services, Inc. has a 12 month low of $310.42 and a 12 month high of $415.73. The company has a current ratio of 2.61, a quick ratio of 1.95 and a debt-to-equity ratio of 0.03. The stock’s fifty day simple moving average is $376.22 and its 200 day simple moving average is $364.09.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, April 25th. The medical instruments supplier reported $1.56 EPS for the quarter, topping the consensus estimate of $1.29 by $0.27. The business had revenue of $695.40 million for the quarter, compared to the consensus estimate of $670.62 million. West Pharmaceutical Services had a return on equity of 20.57% and a net margin of 19.42%. The firm’s revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the business posted $1.98 EPS. On average, research analysts predict that West Pharmaceutical Services, Inc. will post 7.76 EPS for the current year.

West Pharmaceutical Services Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 7th. Investors of record on Wednesday, July 31st will be paid a dividend of $0.20 per share. This represents a $0.80 annualized dividend and a yield of 0.24%. The ex-dividend date of this dividend is Wednesday, July 31st. West Pharmaceutical Services’s payout ratio is presently 10.55%.

Insider Buying and Selling

In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $358.82, for a total value of $292,438.30. Following the sale, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other West Pharmaceutical Services news, CAO Chad Winters sold 815 shares of West Pharmaceutical Services stock in a transaction dated Monday, March 11th. The stock was sold at an average price of $358.82, for a total value of $292,438.30. Following the sale, the chief accounting officer now owns 1,309 shares of the company’s stock, valued at approximately $469,695.38. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Charles Witherspoon sold 2,019 shares of West Pharmaceutical Services stock in a transaction dated Wednesday, February 28th. The shares were sold at an average price of $358.62, for a total value of $724,053.78. Following the completion of the sale, the vice president now directly owns 1,979 shares in the company, valued at approximately $709,708.98. The disclosure for this sale can be found here. In the last quarter, insiders have sold 139,978 shares of company stock valued at $50,852,672. 0.53% of the stock is owned by company insiders.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.